Amgen 2013 Annual Report Download - page 48

Neulasta®/NEUPOGEN®
Total Neulasta® and total NEUPOGEN® sales by geographic region were as follows (dollar amounts in millions):





Neulasta® — U.S. $3,499
9 %
$3,207
7 %
$3,006
Neulasta® — ROW 893
1 %
885
(6)%
946
Total Neulasta®4,392
7 %
4,092
4 %
3,952
NEUPOGEN® — U.S. 1,169
16 %
1,007
5 %
959
NEUPOGEN® — ROW 229
(9)%
253
(16)%
301
Total NEUPOGEN®1,398
11 %
1,260
— %
1,260
Total Neulasta®/NEUPOGEN®$5,790
8 %
$5,352
3 %
$5,212
The increase in global Neulasta® sales for 2013 was driven by an increase in the average net sales price in the United States, offset partially by a
decline in units. The increase in global NEUPOGEN ® sales for 2013 was driven by a $155-million order from the U.S. government. Excluding the special
order, U.S. sales grew only 1% and global sales declined 1%. Units declined in 2013 in both the United States and ROW.
The increase in U.S. Neulasta® sales for 2012 was driven by an increase in the average net sales price. The decrease in ROW Neulasta ® sales for 2012
was due primarily to a decrease in unit demand from loss of share to biosimilars in Europe and a decrease in the average net sales price.
The increase in U.S. NEUPOGEN® sales for 2012 was driven by an increase in the average net sales price. The decrease in ROW NEUPOGEN ®
sales for 2012 was driven by a decrease in unit demand from loss of share to biosimilars in Europe.
Our material U.S. patents for filgrastim (NEUPOGEN ®) expired in December 2013. We now face competition in the United States, which may have a
material adverse impact over time on future sales of NEUPOGEN ® and, to a lesser extent, Neulasta®. Our outstanding material U.S. patent for pegfilgrastim
(Neulasta®) expires in 2015.
Future Neulasta®/NEUPOGEN® sales will also depend, in part, on the development of new protocols, tests and/or treatments for cancer and/or new
chemotherapy treatments or alternatives to chemotherapy that may have reduced and may continue to reduce the use of chemotherapy in some patients.
ENBREL
Total ENBREL sales by geographic region were as follows (dollar amounts in millions):





ENBREL — U.S.
$4,256
7%
$3,967
15%
$ 3,458
ENBREL — Canada
295
10%
269
11%
243
Total ENBREL
$4,551
7%
$ 4,236
14%
$3,701
The increase in ENBREL sales for 2013 was driven primarily by an increase in the average net sales price offset partially by slight unit declines.
The increase in ENBREL sales for 2012 was driven primarily by an increase in the average net sales price and, to a lesser extent, an increase in unit
demand.
ENBREL also faces increased competition. See Item 1. Business — Marketing, Distribution and Selected Marketed Products — Competition.
Aranesp®
Total Aranesp® sales by geographic region were as follows (dollar amounts in millions):





Aranesp® — U.S. $747
(4)%
$ 782
(21)%
$986
Aranesp® — ROW 1,164
(7)%
1,258
(4)%
1,317
Total Aranesp®$1,911
(6)%
$2,040
(11)%
$2,303
42